References
- Cate, T. R. 1998. Impact of influenza and other community- acquired viruses. Semin. Respir. Infect. 13: 17-23.
- Greenberg, S. B. 2007. Rhinovirus and coronavirus infections. Semin. Respir. Crit. Care Med. 28: 182-192. https://doi.org/10.1055/s-2007-976490
- Heikkinen, T. 2000. Role of viruses in the pathogenesis of acute otitis media. Pediatr. Infect. Dis. J. 19: S17-22. https://doi.org/10.1097/00006454-200005001-00004
- Mahony, J. B., A. Petrich, and M. Smieja. 2011. Molecular diagnosis of respiratory virus infections. Crit. Rev. Clin. Lab. Sci. 48: 217-249. https://doi.org/10.3109/10408363.2011.640976
- See, H. and P. Wark. 2008. Innate immune response to viral infection of the lungs. Paediatr. Respir. Rev. 9: 243-250. https://doi.org/10.1016/j.prrv.2008.04.001
- Bartlett, J. A., A. J. Fischer, and P. B. McCray, Jr. 2008. Innate immune functions of the airway epithelium. Contrib. Microbiol. 15: 147-163.
- Oshansky, C. M., W. Zhang, E. Moore, and R. A. Tripp. 2009. The host response and molecular pathogenesis associated with respiratory syncytial virus infection. Future Microbiol. 4: 279-297. https://doi.org/10.2217/fmb.09.1
- Schwarze, J. and K. J. Mackenzie. 2013. Novel insights into immune and inflammatory responses to respiratory viruses. Thorax. 68: 108-110. https://doi.org/10.1136/thoraxjnl-2012-202291
- Sajjan, U. S. 2013. Susceptibility to viral infections in chronic obstructive pulmonary disease: role of epithelial cells. Curr. Opin. Pulm. Med. 19: 125-132. https://doi.org/10.1097/MCP.0b013e32835cef10
- Averett, D. R., S. P. Fletcher, W. Li, S. E. Webber, and J. R. Appleman. 2007. The pharmacology of endosomal TLR agonists in viral disease. Biochem. Soc. Trans. 35: 1468-1472. https://doi.org/10.1042/BST0351468
- Sandor, F. and M. Buc. 2005. Toll-like receptors. II. Distribution and pathways involved in TLR signalling. Folia. Biol. (Praha). 51: 188-197.
- Kurt-Jones, E. A., L. Popova, L. Kwinn, L. M. Haynes, L. P. Jones, R. A. Tripp, E. E. Walsh, M. W. Freeman, D. T. Golenbock, L. J. Anderson, and R. W. Finberg. 2000. Pattern recognition receptors TLR4 and CD14 mediate response to respiratory syncytial virus. Nat. Immunol. 1: 398-401. https://doi.org/10.1038/80833
- Haynes, L. M., D. D. Moore, E. A. Kurt-Jones, R. W. Finberg, L. J. Anderson, and R. A. Tripp. 2001. Involvement of toll-like receptor 4 in innate immunity to respiratory syncytial virus. J. Virol. 75: 10730-10737. https://doi.org/10.1128/JVI.75.22.10730-10737.2001
- Awomoyi, A. A., P. Rallabhandi, T. I. Pollin, E. Lorenz, M. B. Sztein, M. S. Boukhvalova, V. G. Hemming, J. C. Blanco, and S. N. Vogel. 2007. Association of TLR4 polymorphisms with symptomatic respiratory syncytial virus infection in highrisk infants and young children. J. Immunol. 179: 3171-3177. https://doi.org/10.4049/jimmunol.179.5.3171
- Goodbourn, S. and R. E. Randall. 2009. The regulation of type I interferon production by paramyxoviruses. J. Interferon Cytokine Res. 29: 539-547. https://doi.org/10.1089/jir.2009.0071
- Le Goffic, R., J. Pothlichet, D. Vitour, T. Fujita, E. Meurs, M. Chignard, and M. Si-Tahar. 2007. Cutting Edge: Influenza A virus activates TLR3-dependent inflammatory and RIG-I-dependent antiviral responses in human lung epithelial cells. J. Immunol. 178: 3368-72. https://doi.org/10.4049/jimmunol.178.6.3368
- Dempoya, J., T. Matsumiya, T. Imaizumi, R. Hayakari, F. Xing, H. Yoshida, K. Okumura, and K. Satoh. 2012. Double-stranded RNA induces biphasic STAT1 phosphorylation by both type I interferon (IFN)-dependent and type I IFN-independent pathways. J. Virol. 86: 12760-12769. https://doi.org/10.1128/JVI.01881-12
- O'Neill, L. A. and A. G. Bowie. 2007. The family of five: TIR-domain-containing adaptors in Toll-like receptor signalling. Nat. Rev. Immunol. 7: 353-364. https://doi.org/10.1038/nri2079
- Oshansky, C. M., T. M. Krunkosky, J. Barber, L. P. Jones, and R. A. Tripp. 2009. Respiratory syncytial virus proteins modulate suppressors of cytokine signaling 1 and 3 and the type I interferon response to infection by a toll-like receptor pathway. Viral Immunol. 22: 147-161. https://doi.org/10.1089/vim.2008.0098
- Moore, E. C., J. Barber, and R. A. Tripp. 2008. Respiratory syncytial virus (RSV) attachment and nonstructural proteins modify the type I interferon response associated with suppressor of cytokine signaling (SOCS) proteins and IFN-stimulated gene-15 (ISG15). Virol. J. 5: 116. https://doi.org/10.1186/1743-422X-5-116
- Tripp, R. A., C. Oshansky, and R. Alvarez. 2005. Cytokines and respiratory syncytial virus infection. Proc. Am. Thorac. Soc. 2: 147-149. https://doi.org/10.1513/pats.200502-014AW
- Lopusna, K., I. Rezuchova, T. Betakova, L. Skovranova, J. Tomaskova, L. Lukacikova, and P. Kabat. 2013. Interferons lambda, new cytokines with antiviral activity. Acta Virol. 57: 171-179. https://doi.org/10.4149/av_2013_02_171
- Kotenko, S. V. 2011. IFN-lambdas. Curr. Opin. Immunol. 23: 583-590. https://doi.org/10.1016/j.coi.2011.07.007
- Hauser, M. J., D. Dlugolenski, M. R. Culhane, D. E. Wentworth, S. M. Tompkins, and R. A. Tripp. 2013. Antiviral responses by Swine primary bronchoepithelial cells are limited compared to human bronchoepithelial cells following influenza virus infection. PLoS One 8: e70251. https://doi.org/10.1371/journal.pone.0070251
- Teng, M. N. 2012. The non-structural proteins of RSV: targeting interferon antagonists for vaccine development. Infect. Disord. Drug Targets 12: 129-137. https://doi.org/10.2174/187152612800100170
- Thornburg, N. J., S. L. Hayward, and J. E. Crowe, Jr. 2012. Respiratory syncytial virus regulates human microRNAs by using mechanisms involving beta interferon and NF-kappaB. MBio. 3: e00220-12.
- Munir, S., C. Le Nouen, C. Luongo, U. J. Buchholz, P. L. Collins, and A. Bukreyev. 2008. Nonstructural proteins 1 and 2 of respiratory syncytial virus suppress maturation of human dendritic cells. J. Virol. 82: 8780-8796. https://doi.org/10.1128/JVI.00630-08
- Tripp, R. A., L. Jones, and L. J. Anderson. 2000. Respiratory syncytial virus G and/or SH glycoproteins modify CC and CXC chemokine mRNA expression in the BALB/c mouse. J. Virol. 74: 6227-6229. https://doi.org/10.1128/JVI.74.13.6227-6229.2000
- Tripp, R. A., D. Moore, and L. J. Anderson. 2000. TH(1)- and TH(2)-TYPE cytokine expression by activated t lymphocytes from the lung and spleen during the inflammatory response to respiratory syncytial virus. Cytokine 12: 801-807. https://doi.org/10.1006/cyto.1999.0615
- Tripp, R. A., D. Moore, L. Jones, W. Sullender, J. Winter, and L. J. Anderson. 1999. Respiratory syncytial virus G and/or SH protein alters Th1 cytokines, natural killer cells, and neutrophils responding to pulmonary infection in BALB/c mice. J. Virol. 73: 7099-7107.
- Harcourt, J., R. Alvarez, L. P. Jones, C. Henderson, L. J. Anderson, and R. A. Tripp. 2006. Respiratory syncytial virus G protein and G protein CX3C motif adversely affect CX3CR1+ T cell responses. J. Immunol. 176: 1600-1608. https://doi.org/10.4049/jimmunol.176.3.1600
- Tripp, R. A. and L. J. Anderson. 1998. Cytotoxic T-lymphocyte precursor frequencies in BALB/c mice after acute respiratory syncytial virus (RSV) infection or immunization with a formalin-inactivated RSV vaccine. J. Virol. 72: 8971-8975.
- Bakre, A., P. Mitchell, J. K. Coleman, L. P. Jones, G. Saavedra, M. Teng, S. M. Tompkins, and R. A. Tripp. 2012. Respiratory syncytial virus modifies microRNAs regulating host genes that affect virus replication. J. Gen. Virol. 93: 2346-2356. https://doi.org/10.1099/vir.0.044255-0
- Tripp, R. A., L. P. Jones, L. M. Haynes, H. Zheng, P. M. Murphy, and L. J. Anderson. 2001. CX3C chemokine mimicry by respiratory syncytial virus G glycoprotein. Nat. Immunol. 2: 732-738. https://doi.org/10.1038/90675
- Haynes, L. M., L. P. Jones, A. Barskey, L. J. Anderson, and R. A. Tripp. 2003. Enhanced disease and pulmonary eosinophilia associated with formalin-inactivated respiratory syncytial virus vaccination are linked to G glycoprotein CX3CCX3CR1 interaction and expression of substance P. J. Virol. 77: 9831-9844. https://doi.org/10.1128/JVI.77.18.9831-9844.2003
- Tripp, R. A., A. Dakhama, L. P. Jones, A. Barskey, E. W. Gelfand, and L. J. Anderson. 2003. The G glycoprotein of respiratory syncytial virus depresses respiratory rates through the CX3C motif and substance P. J. Virol. 77: 6580-6584. https://doi.org/10.1128/JVI.77.11.6580-6584.2003
- Li, X. Q., Z. F. Fu, R. Alvarez, C. Henderson, and R. A. Tripp. 2006. Respiratory syncytial virus (RSV) infects neuronal cells and processes that innervate the lung by a process involving RSV G protein. J. Virol. 80: 537-540. https://doi.org/10.1128/JVI.80.1.537-540.2006
- Zhang, W., Y. Choi, L. M. Haynes, J. L. Harcourt, L. J. Anderson, L. P. Jones, and R. A. Tripp. 2010. Vaccination to induce antibodies blocking the CX3C-CX3CR1 interaction of respiratory syncytial virus G protein reduces pulmonary inflammation and virus replication in mice. J. Virol. 84: 1148-1157. https://doi.org/10.1128/JVI.01755-09
- Kauvar, L. M., J. L. Harcourt, L. M. Haynes, and R. A. Tripp. 2010. Therapeutic targeting of respiratory syncytial virus G-protein. Immunotherapy 2: 655-661. https://doi.org/10.2217/imt.10.53
- Miao, C., G. U. Radu, H. Caidi, R. A. Tripp, L. J. Anderson, and L. M. Haynes. 2009. Treatment with respiratory syncytial virus G glycoprotein monoclonal antibody or F(ab')2 components mediates reduced pulmonary inflammation in mice. J. Gen. Virol. 90: 1119-1123. https://doi.org/10.1099/vir.0.009308-0
- Haynes, L. M., H. Caidi, G. U. Radu, C. Miao, J. L. Harcourt, R. A. Tripp, and L. J. Anderson. 2009. Therapeutic monoclonal antibody treatment targeting respiratory syncytial virus (RSV) G protein mediates viral clearance and reduces the pathogenesis of RSV infection in BALB/c mice. J. Infect. Dis. 200: 439-447. https://doi.org/10.1086/600108
- Collarini, E. J., F. E. Lee, O. Foord, M. Park, G. Sperinde, H. Wu, W. D. Harriman, S. F. Carroll, S. L. Ellsworth, L. J. Anderson, R. A. Tripp, E. E. Walsh, B. A. Keyt, and L. M. Kauvar. 2009. Potent high-affinity antibodies for treatment and prophylaxis of respiratory syncytial virus derived from B cells of infected patients. J. Immunol. 183: 6338-6345. https://doi.org/10.4049/jimmunol.0901373
- Harcourt, J. L., R. A. Karron, and R. A. Tripp. 2004. Anti-G protein antibody responses to respiratory syncytial virus infection or vaccination are associated with inhibition of G protein CX3C-CX3CR1 binding and leukocyte chemotaxis. J. Infect. Dis. 190: 1936-1940. https://doi.org/10.1086/425516
- Choi, Y., C. S. Mason, L. P. Jones, J. Crabtree, P. A. Jorquera, and R. A. Tripp. 2012. Antibodies to the central conserved region of respiratory syncytial virus (RSV) G protein block RSV G protein CX3C-CX3CR1 binding and cross-neutralize RSV A and B strains. Viral Immunol. 25: 193-203.
- Beeler, J. A. and M. C. Eichelberger. 2013. Influenza and respiratory syncytial virus (RSV) vaccines for infants: safety, immunogenicity, and efficacy. Microb. Pathog. 55: 9-15. https://doi.org/10.1016/j.micpath.2012.11.013
- Schmidt, A. C. 2011. Progress in respiratory virus vaccine development. Semin. Respir. Crit. Care Med. 32: 527-540. https://doi.org/10.1055/s-0031-1283289
- DeVincenzo, J. P. 2012. The promise, pitfalls and progress of RNA-interference-based antiviral therapy for respiratory viruses. Antivir. Ther. 17: 213-225. https://doi.org/10.3851/IMP2064
- Alvarez, R., S. Elbashir, T. Borland, I. Toudjarska, P. Hadwiger, M. John, I. Roehl, S. S. Morskaya, R. Martinello, J. Kahn, M. Van Ranst, R. A. Tripp, J. P. DeVincenzo, R. Pandey, M. Maier, L. Nechev, M. Manoharan, V. Kotelianski, and R. Meyers. 2009. RNA interference-mediated silencing of the respiratory syncytial virus nucleocapsid defines a potent antiviral strategy. Antimicrob. Agents Chemother. 53: 3952- 3962. https://doi.org/10.1128/AAC.00014-09
- Zhang, W. and R. A. Tripp. 2008. RNA interference inhibits respiratory syncytial virus replication and disease pathogenesis without inhibiting priming of the memory immune response. J. Virol. 82: 12221-12231. https://doi.org/10.1128/JVI.01557-08
- Bakre, A., L. E. Andersen, V. Meliopoulos, K. Coleman, X. Yan, P. Brooks, J. Crabtree, S. M. Tompkins, and R. A. Tripp. 2013. Identification of host kinase genes required for influenza virus replication and the regulatory role of MicroRNAs. PLoS One 8: e66796. https://doi.org/10.1371/journal.pone.0066796
- Perwitasari, O., X. Yan, S. Johnson, C. White, P. Brooks, S. M. Tompkins, and R. A. Tripp. 2013. Targeting organic anion transporter 3 with probenecid as a novel anti-influenza a virus strategy. Antimicrob. Agents Chemother. 57: 475-483. https://doi.org/10.1128/AAC.01532-12
- Meliopoulos, V. A., L. E. Andersen, P. Brooks, X. Yan, A. Bakre, J. K. Coleman, S. M. Tompkins, and R. A. Tripp. 2012. MicroRNA regulation of human protease genes essential for influenza virus replication. PLoS One 7: e37169. https://doi.org/10.1371/journal.pone.0037169
- Meliopoulos, V. A., L. E. Andersen, K. F. Birrer, K. J. Simpson, J. W. Lowenthal, A. G. Bean, J. Stambas, C. R. Stewart, S. M. Tompkins, V. W. van Beusechem, I. Fraser, M. Mhlanga, S. Barichievy, Q. Smith, D. Leake, J. Karpilow, A. Buck, G. Jona, and R. A. Tripp. 2012. Host gene targets for novel influenza therapies elucidated by high-throughput RNA interference screens. FASEB J. 26: 1372-1386. https://doi.org/10.1096/fj.11-193466
- Tran, A. T., M. N. Rahim, C. Ranadheera, A. Kroeker, J. P. Cortens, K. J. Opanubi, J. A. Wilkins, and K. M. Coombs. 2013. Knockdown of specific host factors protects against influenza virus-induced cell death. Cell Death Dis. 4: e769. https://doi.org/10.1038/cddis.2013.296
- Prusty, B. K., A. Karlas, T. F. Meyer, and T. Rudel. 2011. Genome-wide RNAi screen for viral replication in mammalian cell culture. Methods Mol. Biol. 721: 383-395. https://doi.org/10.1007/978-1-61779-037-9_24
- Panda, D. and S. Cherry. 2012. Cell-based genomic screening: elucidating virus-host interactions. Curr. Opin. Virol. 2: 784-792. https://doi.org/10.1016/j.coviro.2012.10.007
- Kassner, P. D. 2008. Discovery of novel targets with high throughput RNA interference screening. Comb. Chem. High Throughput Screen 11: 175-184. https://doi.org/10.2174/138620708783877744
Cited by
- Modulation of host adaptive immunity by hRSV proteins vol.5, pp.7, 2014, https://doi.org/10.4161/viru.32225
- A Cross-Study Biomarker Signature of Human Bronchial Epithelial Cells Infected with Respiratory Syncytial Virus vol.2016, pp.None, 2013, https://doi.org/10.1155/2016/3605302
- HCoV-IMDB: Database for the Analysis of Interactions between HCoV and Host Immune Proteins vol.8, pp.1, 2019, https://doi.org/10.7236/ijasc.2019.8.1.1
- Toll-like receptor 4-mediated respiratory syncytial virus disease and lung transcriptomics in differentially susceptible inbred mouse strains vol.51, pp.12, 2013, https://doi.org/10.1152/physiolgenomics.00101.2019
- Respiratory Syncytial Virus (RSV) G Protein Vaccines With Central Conserved Domain Mutations Induce CX3C-CX3CR1 Blocking Antibodies vol.13, pp.2, 2013, https://doi.org/10.3390/v13020352
- Immunopathology of RSV: An Updated Review vol.13, pp.12, 2013, https://doi.org/10.3390/v13122478